Immunology drug development is no longer a single-pathway biologics story.

Pharma is assembling mechanism stacks designed to work across diseases, hedge biological risk and replace at-risk franchises elsewhere in their portfolio. The strategy map shows the state of play: 41 distinct mechanisms and a market that has evolved in three stages.

Stage 1: the blockbuster biologic

TNF, IL-12/23, IL-17 and IL-4/13 established the model: validate a single pathway and use that to expand across multiple diseases.

Stage 2: rise of orals

JAK and S1P modulators demonstrated demand for systemic oral therapies, but also showed that convenience is commercially viable only when paired with an acceptable chronic-use safety profile. More recent attempts include selective TYK2 inhibitors, oral IL-23 and other targeted pathway modulators.

Stage 3: the mechanism stack

The map includes a dizzying range of modalities, including degraders, bispecifics, TCEs, CAR-T and more. It's not about which cytokine wins, but how to cover the most strategically useful parts of the treatment landscape: combining convenient chronic control AND precision biologics AND immune reset in one portfolio.

This wave matches what happened in oncology: once a target is validated, value shifts towards patient selection, combo architecture and asset-level differentiation. While one mechanism can create several commercial shots on goal, I&I's biological heterogeneity makes it unlikely we'll see a single winner. There will be room for segmentation, sequencing and multiple standards of care.

Across top pharma, that is producing a barbell strategy. Chronic substitution is about making advanced treatment easier and moving it earlier, initially suited for larger, less refractory populations. Examples include oral IL-23, TYK2 and STAT6/IRAK4 degraders. Immune reset is about deep, potentially drug-free remission, initially suited for severe, treatment-refractory disease. Examples include CD19 CAR-T/TCEs, BCMA/CD19 or CD38.

Most are placing bets across both areas, recognizing that owning a ladder of interventions and matching patients to each rung will be key as I&I fractures in much the same way oncology did.